Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bieck

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Psychiatrische Praxis|August 1, 1989
[Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies]P R Bieck
Journal of Neural Transmission. Supplementum|January 1, 1989
Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitorsP R Bieck, K H Antonin
Annual Review of Pharmacology and Toxicology|April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domainsPeter R Bieck, William Z Potter
European Journal of Clinical Pharmacology|January 1, 1982
Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteersP R Bieck, K H Antonin
Journal of Clinical Psychopharmacology|August 1, 1988
Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjectsP R Bieck, K H Antonin
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1976
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and ratU Klotz, K H Antonin, P R Bieck
European Journal of Clinical Pharmacology|June 15, 1976
Comparison of the pharmacokinetics of diazepam after single and subchronic dosesU Klotz, K H Antonin, P R Bieck
Methods and Findings in Experimental and Clinical Pharmacology|October 1, 1987
Intra-subject variability of platelet alpha 2-adrenoceptor binding sites in healthy volunteersI W Reimann, C Britzelmeier, P R Bieck
Journal of Neural Transmission. Supplementum|January 1, 1990
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjectsP R Bieck, E Nilsson, K H Antonin
Clinical Neuropharmacology|January 1, 1993
Clinical pharmacology of reversible monoamine oxidase-A inhibitorsP R Bieck, K H Antonin, E Schmidt
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Psychiatrische Praxis|August 1, 1989
[Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies]P R Bieck
Journal of Neural Transmission. Supplementum|January 1, 1989
Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitorsP R Bieck, K H Antonin
Annual Review of Pharmacology and Toxicology|April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domainsPeter R Bieck, William Z Potter
European Journal of Clinical Pharmacology|January 1, 1982
Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteersP R Bieck, K H Antonin
Journal of Clinical Psychopharmacology|August 1, 1988
Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjectsP R Bieck, K H Antonin
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1976
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and ratU Klotz, K H Antonin, P R Bieck
European Journal of Clinical Pharmacology|June 15, 1976
Comparison of the pharmacokinetics of diazepam after single and subchronic dosesU Klotz, K H Antonin, P R Bieck
Methods and Findings in Experimental and Clinical Pharmacology|October 1, 1987
Intra-subject variability of platelet alpha 2-adrenoceptor binding sites in healthy volunteersI W Reimann, C Britzelmeier, P R Bieck
Journal of Neural Transmission. Supplementum|January 1, 1990
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjectsP R Bieck, E Nilsson, K H Antonin
Clinical Neuropharmacology|January 1, 1993
Clinical pharmacology of reversible monoamine oxidase-A inhibitorsP R Bieck, K H Antonin, E Schmidt
Pageof 4